Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of age undergoing contrast-enhanced MRI

Next Previous
Trial Profile

Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of age undergoing contrast-enhanced MRI

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadopiclenol (Primary)
  • Indications CNS disorders
  • Focus Pharmacokinetics
  • Sponsors Guerbet

Most Recent Events

  • 25 Jul 2022 Results evaluating the pharmacokinetic (PK) profile, safety, and efficacy of gadopiclenol in children aged 2 to 17 years, published in the Investigative Radiology
  • 31 Oct 2020 This trial has been completed in Poland according to European Clinical Trials Database record.
  • 25 Aug 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top